Renowned for its ‘in-depth understanding’ of the healthcare and life sciences industries, Fangda Partners excels in licensing transactions, capital markets, and private equity investments. Josh Shin leads the practice, offering significant expertise in regulatory issues related to clinical trials, R&D, and patient-centric transformations. Diana Li is sought after by PE/VC funds and international pharmaceutical companies for acquisitions and investments in medical device, pharmaceutical, and medical laboratory firms. Meanwhile, Henry He specialises in cross-border transactions, including product and technology in- and out-licensing.
Legal 500 redaktioneller Kommentar
- Profil
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘In addition to in-depth understanding of the biopharmaceutical industry and keen insight into the current status of the industry, they also provide a variety of services, including compliance, antitrust, litigation, real estate, etc., which is relatively comprehensive.’
‘Josh Shin has worked in the industry for many years and can respond quickly and can meet various requirements of customers. Bella Wang is diligent, hardworking, and gives timely feedback.’
‘Fangda can provide legal guidance on transactions, daily legal advice, data and personal information protection, and responding to law enforcement investigations in the healthcare industry.’
‘Josh Shin has a deep understanding of the medical industry and major legal issues and is good at communication. Gil Zhang has extensive experience in cross-border data transmission in the pharmaceutical industry and provides practical legal guidance on data protection and data transmission for companies in China, as well as the latest trends in regulatory supervision.’
‘Fangda is a very dynamic law firm which can provide a full range of services to meet various clients' needs.’
‘Diana Li is a very experienced and well-organised lawyer in the healthcare industry who can always bring insightful suggestions and ideas to clients.’
‘The team is very hardworking, responsive and professional.’
‘The team has a wide range of professional fields, good diversity, and efficient collaboration.’
Kernmandanten
- AnHeart Therapeutics
- Chengdu Kanghua Biological Products Co., Ltd.
- WuXi XDC Cayman Inc.
- AstraZeneca
- Tianjing Bio
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Hasten Biopharma
- Pfizer
- UCB
- Smith Nephew
Highlight-Mandate
- Represented AnHeart Therapeutics on its acquisition by Nuvation Bio in an all-stock transaction.
- Represented Kanghua in granting HilleVax the exclusive rights to develop, manufacture and commercialize Kanghua’s hexavalent virus-like particle vaccine candidate for norovirus in the ex-Greater China territory.
- Assisted WuXi XDC as its PRC and HK legal advisor in its spin-off listing on the HKEx.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Josh Shin
Weitere Kernanwält*innen
Diana Li; Henry He; Bella Wang; Gil Zhang